Table 1:
Characteristics of patients receiving non-fused versus fused biopsies.
| Method of biopsy | P | ||
|---|---|---|---|
| Non-fused (n=121) | Fused (n=90) | ||
| Age (y) | 67 (59 to 70) | 65 (59 to 70) | 0.48 |
| Race n (%) | |||
| African American | 10 (8) | 9 (10) | 0.76 |
| White | 85 (71) | 65 (72) | |
| Hispanic | 5 (4) | 1 (1) | |
| Other | 15 (12) | 11 (12) | |
| Declined to answer | 6 (5) | 4 (5) | |
| Family history n (%) | |||
| No | 56 (46) | 46 (52) | 0.78 |
| Yes | 32 (27) | 22 (24) | |
| Unknown | 33 (27) | 22 (24) | |
| Digital rectal examination findings n (%) | |||
| Normal | 15 (12) | 39 (43) | <0.001 |
| Abnormal | 80 (66) | 34 (38) | |
| Not documented | 26 (22) | 17 (19) | |
| Prior biopsy n (%) | |||
| None | 57 (47) | 53 (59) | 0.10 |
| Negative | 64 (53) | 37 (41) | |
| PIRADS score | |||
| 3 | 57 (47) | 37 (41) | 0.49 |
| 4 | 50 (41) | 38 (42) | |
| 5 | 14 (12) | 15 (17) | |
| MR prostate volume (cm3) | 51 (34 to 77) | 49 (34 to 74) | 0.88 |
| Lesion maximum size (mm) | 10 (7 to 12) | 12 (7 to 15) | 0.19 |
| Location of lesion in prostate MR | |||
| Peripheral zone | 86 (72) | 58 (65) | 0.66 |
| Transition zone | 27 (22) | 21 (24) | |
| Peripheral plus transition zone | 4 (3) | 7 (8) | |
| Central zone | 4 (3) | 3 (3) | |
| Prostate Health Index (PHI) (Score) | 39.5 (29.4 to 54.8) | 42.5 (30.0 to 53.8) | 0.06 |
| PHI density | 0.77 (0.47 to 1.31) | 0.88 (0.53 to 1.38) | 0.16 |
| Prostate specific antigen (PSA) ng/mL | 5.6 (3.3 to 9.5) | 5.6 (4.0 to 9.4) | 0.22 |
| PSA density | 0.10 (0.07 to 0.17) | 0.11 (0.08 to 0.21) | 0.12 |
| Biopsy Gleason Grade Group n (%)a | |||
| GG1 | 12 (10) | 16 (18) | <0.001 |
| GG2 | 13 (10) | 22 (24) | |
| GG3 | 6 (5) | 3 (3) | |
| GG4 | 2 (2) | 6 (7) | |
| GG5 | 0 | 2 (2) | |
Data presented as n (%) of column or median (quartile).
a
Gleason Grade Group (GGx) based on 2014 International Society of Urological Pathology Consensus Conference.